| Filed | Description | |
|---|---|---|
| 11/6/25 | 1.01 Material Agreement | → |
| 7/30/25 | 1.01 Material Agreement | → |
| 1/17/25 | 1.01 Material Agreement | → |
| 1/15/25 | 1.01 Material Agreement | → |
| 1/14/25 | 1.01 Material Agreement | → |
| 12/26/24 | 1.01 Material Agreement | → |
| ↓ 8 more | ||
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018.